Damora Therapeutics, Inc. DMRA
$20.55
▼ -2.72% 24H
About
Damora Therapeutics, Inc. is a clinical-stage biotechnology company developing small molecule therapeutics targeting fibrosis, cancer, inflammation, and related diseases. Its lead candidates include GB3226, a preclinical dual inhibitor of ENL-YEATS and FLT3 aimed at blood cancer indications such as acute myeloid leukem…
SectorHealthcare
ExchangeNASDAQ
IndustryBiotechnology
CountryUnited States
Employees7
TickerDMRA
Statistics
Market Cap$1.24B
Revenue (TTM)—
Net Income-$209.8M
Net Margin—
EPS$3.98
P/E-5.20
P/S—
P/B3.48
EV/EBITDA-14.12
ROE-89.5%
Dividend Yield—
Price$20.55
Data: Twelve Data · Revenue = mcap / P/S